Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nurix Therapeutics Inc 1700 OWENS STREET SUITE 205 SAN FRANCISCO CA 94158 USA

www.nurixtx.com P: 415-660-5320 F: 415-525-4200

Description:

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 625,692
Enterprise Value, $K 571,062
Shares Outstanding, K 49,151
Annual Sales, $ 76,990 K
Annual Net Income, $ -143,950 K
Last Quarter Sales, $ 16,590 K
Last Quarter Net Income, $ -41,520 K
EBIT, $ -157,330 K
EBITDA, $ -149,100 K
60-Month Beta 2.10
% of Insider Shareholders 7.20%
% of Institutional Shareholders 0.00%
Float, K 45,612
% Float 92.80%
Short Volume Ratio 0.48

Growth:

1-Year Return 36.54%
3-Year Return -52.75%
5-Year Return 0.00%
5-Year Revenue Growth 105.58%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.76 on 04/10/24
Latest Earnings Date 04/11/24
Earnings Per Share ttm -2.66
EPS Growth vs. Prev Qtr 1.30%
EPS Growth vs. Prev Year -1.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NRIX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -67.09%
Return-on-Assets % -43.62%
Profit Margin % -186.97%
Debt/Equity 0.00
Price/Sales 8.35
Price/Cash Flow N/A
Price/Book 3.50
Book Value/Share 3.43
Interest Coverage -2.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar